BioSpace News Archive

Aadi Bioscience, Inc. announced that Brendan Delaney has resigned for personal reasons from his position as Chief Executive Officer, President, and member of the Board of Directors of the Company.

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 17 new employees.

Summit Therapeutics Inc. announced the successful closing of its fully-subscribed $500 million rights offering.

Surgalign Holdings, Inc. announced its participation at the 2023 American Academy of Orthopaedic Surgeons Annual Meeting, which will take place March 7-11, 2023 in Las Vegas, Nevada.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data analyzing the long-term outcomes of treating tardive dyskinesia (TD) with INGREZZA® (valbenazine) capsules in older (≥55 years) and elderly (≥65 years) patients from two studies (KINECT™ 3-extension and KINECT™ 4).

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI™ (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology (AAN) annual meeting, being held April 22 – 27, 2023 in Boston, Massachusetts.

NanoVibronix, Inc today announced that on February 28, 2023, the Company received official notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with all applicable criteria for continued listing on The Nasdaq Capital Market.

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that through its wholly owned subsidiary, Radiopharm Theranostics (USA) Inc., it has entered into a binding agreement to acquire Pharma15 Corporation (Pharma15).

Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today reported that data from a recent peer-reviewed clinical study involving Bentrio nasal spray’s residence time and other rheological properties demonstrated superiority vs. a saline control.

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2022.